← back to search

Meng Zhao

Tsinghua University · CN

Area of research

Neurology · Radiology, Nuclear Medicine and Imaging

Research interest

Research interests include Biology, Druggability, Mevalonate pathway, Adjuvant, Vaccine adjuvant, and Autoimmune encephalitis.

h-index

—

citations

296

works

3

NIH funding

—

primary concept

—

email

✉ Find email ↗

Recent publications

Permissive central tolerance plus defective peripheral checkpoints license pathogenic memory B cells in CASPR2-antibody encephalitis

Science Advances 2025cited by 8position: middledoi

Ultrahigh frequencies of peripherally matured LGI1- and CASPR2-reactive B cells characterize the cerebrospinal fluid in autoimmune encephalitis

Proceedings of the National Academy of Sciences 2024cited by 37position: middledoi

The Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant Discovery

Cell 2018cited by 251position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Xiaoyu Hu · Chengdu University of Traditional Chinese Medicine1 papers (2018–2018)Zhaoyun Zong · Shandong University1 papers (2018–2018)Bo Sun · Centre for Human Genetics1 papers (2024–2024)Eric Oldfield · University of Illinois Urbana-Champaign1 papers (2018–2018)Rohini Mopuri · WinnMed1 papers (2024–2024)Ruby Harrison · University of Oxford1 papers (2024–2024)— · 1 papers (2024–2024)Mingke Zheng · Tsinghua University1 papers (2018–2018)Yonghui Zhang · Jimei University1 papers (2018–2018)Xin Li · New York University1 papers (2018–2018)Liping Li · Tsinghua University1 papers (2018–2018)Ying Li · Luohe Medical College1 papers (2024–2024)Wanli Liu · Nanjing University of Chinese Medicine1 papers (2018–2018)Yan Shi · Fujian Medical University1 papers (2018–2018)Shuai Han · Tsinghua University1 papers (2018–2018)Yonghua Xie · Tsinghua University1 papers (2018–2018)Yun Xia · The Ohio State University1 papers (2018–2018)Xiaoying Zhou · Indiana University School of Medicine1 papers (2018–2018)— · 1 papers (2024–2024)Yunyun Yang · Ministry of Education of the People's Republic of China1 papers (2018–2018)